New drug shows promise in preventing transplant complications
NCT ID NCT04112810
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug tildrakizumab could help prevent graft-versus-host disease (GVHD) in 51 adults receiving a stem cell transplant for blood cancers. GVHD is a serious complication where donor cells attack the patient's body. The goal was to see if adding tildrakizumab to standard care improves survival without severe GVHD or cancer relapse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- AI platform aims to unlock Real-World cancer data on a massive scale
- Can a new tracer light up cancer growth?
- Could a walk a day keep brain fog away after a stem cell transplant?